0001209191-20-043953.txt : 20200729 0001209191-20-043953.hdr.sgml : 20200729 20200729172958 ACCESSION NUMBER: 0001209191-20-043953 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200728 FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200729 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novo Holdings A/S CENTRAL INDEX KEY: 0001388325 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 201058116 BUSINESS ADDRESS: STREET 1: TUBORG HAVNEVEJ 19 CITY: HELLERUP STATE: G7 ZIP: 2900 BUSINESS PHONE: 45 8824 8824 MAIL ADDRESS: STREET 1: TUBORG HAVNEVEJ 19 CITY: HELLERUP STATE: G7 ZIP: 2900 FORMER NAME: FORMER CONFORMED NAME: Novo A/S DATE OF NAME CHANGE: 20070130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-28 0 0001693011 Inozyme Pharma, Inc. INZY 0001388325 Novo Holdings A/S TUBORG HAVNEVEJ 19 HELLERUP G7 2900 DENMARK 0 0 1 0 COMMON STOCK 2020-07-28 4 C 0 2194379 A 2194379 D COMMON STOCK 2020-07-28 4 P 0 375000 16.00 A 2569379 D SERIES A CONVERTIBLE PREFERRED STOCK 2020-07-28 4 C 0 15000000 D COMMON STOCK 2007225 0 D SERIES A-2 CONVERTIBLE PREFERRED STOCK 2020-07-28 4 C 0 1398600 D COMMON STOCK 187154 0 D The Series A Convertible Preferred Stock and Series A-2 Convertible Preferred Stock automatically converted on a 7.4730-for-1 basis into the number of shares of Common Stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment or further consideration. These shares have no expiration date. Represents a purchase from the underwriters in the Issuer's initial public offering. Novo Holdings A/S is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board") has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares. /s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S 2020-07-29